Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Prostatic Neoplasms 2 Overweight 2 Obesity 2 Melanoma 2 Substance Withdrawal Syndrome 1 Skin Neoplasms 1 Kidney Neoplasms 1 Glioma 1 Glioblastoma 1 Chronic Pain 1 Carcinoma, Lobular 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

Temozolomide 156 Bevacizumab 69 Radiotherapy 61 Magnetic Resonance Spectroscopy 59 Irinotecan 31 Surgical Procedures, Operative 23 Radiation 23 Carboplatin 23 Specimen Handling 20 Carmustine 20 Nivolumab 19 Biopsy 17 Lomustine 16 Aminolevulinic Acid 15 Radiotherapy, Intensity-Modulated 13 Cyclophosphamide 13 trametinib 12 pembrolizumab 12 Radiosurgery 12 Erlotinib Hydrochloride 12 fluorodopa F 18 11 Topotecan 11 Everolimus 11 Blood Specimen Collection 11 X-Rays 10 IL13-PE38 10 dabrafenib 9 Etoposide 9 ribociclib 8 poly ICLC 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Glioma × Naltrexone × Clear all

NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed

110 enrolled 9 charts

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡